<DOC>
	<DOCNO>NCT00724997</DOCNO>
	<brief_summary>The purpose phase I trial evaluate safety tolerability GHB01L1 administer single dose intranasal aerosol vaccination influenza A ( H1N1 ) virus . This study perform assess local systemic immune response analyse pharmacokinetics ( shed ) single dose GHB01L1 aerosol administer intranasally .</brief_summary>
	<brief_title>Randomized , Double-blind , Placebo-controlled , Phase I Dose-escalation Study Single Dose GHB01L1 Healthy Volunteers</brief_title>
	<detailed_description>GHB01L1 intend provide novel vaccination influenza virus infection . Data indicate GHB01L1 virus promising , safe immunogenic vaccine candidate high protection efficacy pathogenic wild-type virus challenge . 48 healthy volunteer include phase I dose escalation study investigate five dose level . 8 subject per five dose level additional 8 subject high dose level respectively maximum tolerate dose level randomize ratio 6:2 GHB01L1 placebo accord fix dose escalation plan . After subject one dose level treat observed safety observation period one week , interim safety review perform Expert Committee . The Expert Committee review occur adverse event decide dose escalation next dose level . Only male healthy volunteer age 18-50 seronegative respect apply virus antigen ( antibody titer &lt; 1:10 detected hemagglutination inhibition assay ) randomize . GHB01L1 administer day 1 . After 3 day inpatient period follow-up visit perform day 4 , 5 , 8 , 15 study terminate day 29 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Healthy male volunteer , 1850 year Immune status : seronegative respect apply virus antigen antibody titres &lt; 1:10 detect HAI assay correspond antigen ) Written inform consent participate study Acute febrile illness ( &gt; 37.3°C ) Signs acute chronic upper low tract respiratory illness ( sneeze , cough , tonsillitis , otitis etc . ) History severe atopy Seasonal influenza vaccination 2005/2006 , 2006/2007 and/or 2007/2008 and/or pandemic influenza vaccination H5N1 Known increase tendency nose bleed Volunteers clinically relevant abnormal paranasal anatomy Volunteers clinically relevant abnormal laboratory value Simultaneous treatment immunosuppressive drug incl . Corticosteroids ( ≥2 week ) within 4 week prior study medication application Clinically relevant history renal , hepatic , GI , cardiovascular , haematological , skin , endocrine , neurological immunological disease History leukaemia cancer HIV Hepatitis B C seropositivity Volunteers underwent rhino sinus surgery , surgery another traumatic injury nose within 30 day prior application study medication Volunteers receive antiviral drug , treatment immunoglobulin blood transfusion , investigational drug within four week prior study medication application Volunteers receive antiinflammatory drug 2 day prior study medication application Volunteers likely cope requirement study significant physical mental condition may interfere completion study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>live attenuate flu vaccine</keyword>
	<keyword>Influenza A ( H1N1 )</keyword>
	<keyword>intranasally application</keyword>
	<keyword>replication-deficient influenza virus</keyword>
</DOC>